Is semaglutide safe during pregnancy?

Short answer: no. Semaglutide is not recommended during pregnancy, and its own prescribing information tells patients to stop it well before trying to conceive. The Wegovy label, the higher-dose weight-management version, instructs patients to discontinue the drug at least two months before a planned pregnancy because semaglutide has a long half-life, and to stop it as soon as a pregnancy is recognised^[1]. The label states plainly that weight loss offers no benefit to a pregnant patient and may cause fetal harm^[1]. That is the position to start from, and the rest of this piece explains why the caution is there and what the human data does and does not yet show.

What the semaglutide labels actually say

Both approved semaglutide products carry the same pregnancy caution. The Wegovy prescribing information tells patients to stop at least two months before a planned pregnancy, to discontinue when a pregnancy is recognised, and warns that weight loss during pregnancy may cause fetal harm^[1]. The Ozempic label, the type-2 diabetes version, says there are limited data on semaglutide use in pregnant women, that animal reproduction studies point to potential fetal risk, and that the drug should be used in pregnancy only if the potential benefit justifies the potential risk. It repeats the same instruction to stop at least two months ahead of a planned pregnancy because of the long washout period^[2].

European regulators land in the same place. Semaglutide is a centrally authorised prescription-only medicine across the EU, and the product information for the weight-management version is not written for use in pregnancy^[3]. So this is not one agency being unusually careful. The FDA and the EMA both treat pregnancy as a time to be off the drug, not on it.

The animal data behind the caution

The warnings are not arbitrary. They rest on reproductive-toxicity studies in animals. In those studies semaglutide caused embryofetal death, structural abnormalities and growth changes in rats at maternal exposures below the maximum recommended human dose, and early pregnancy losses and structural abnormalities in rabbits and in cynomolgus monkeys^[1]. The label is careful to note that the human relevance of these animal findings has not been established, so they are a signal rather than a settled fact. But they are exactly the kind of signal that makes a regulator tell people to stop the drug before conception rather than wait and see.

The half-life matters here too. Semaglutide is engineered to linger in the body so it can be dosed once a week. A dose you inject this week is still circulating next week, and for several weeks after your last injection. That is why the instruction is to stop two months ahead of a planned pregnancy, not to stop the day you start trying. The drug does not clear quickly enough for a same-week decision to protect an early pregnancy.

What the human data shows so far

The honest part of the picture is that accidental exposures happen, and researchers have started to pool them. A 2026 systematic review and meta-analysis in Scientific Reports gathered seven cohort studies covering more than 40,000 pregnancies exposed to GLP-1 receptor agonists, the drug family semaglutide belongs to. It found no statistically significant increase in congenital malformations (odds ratio 1.11, 95% confidence interval 0.82 to 1.51), with similarly reassuring results for stillbirth, miscarriage and preterm birth^[4]. Semaglutide was one of the most frequently represented drugs in that pooled data.

That sounds like good news, and to a point it is. But the same authors rate the certainty of the evidence as low and describe their own conclusion as cautiously reassuring, not as an all-clear^[4]. These are observational studies of people who mostly stopped the drug early once they knew they were pregnant, not trials designed to test safety. The reassurance covers inadvertent early exposure. It does not tell anyone that staying on semaglutide through a pregnancy is safe, and no study has been built to answer that question.

What this is not

This is not a claim that a single accidental dose before you knew you were pregnant has harmed your baby. The pooled human data is the opposite of alarming on that specific question^[4]. And it is not a claim that semaglutide is uniquely dangerous in the class. The related investigational triple agonist retatrutide sits in the same cautious position for the same reasons, which we cover in our companion piece on retatrutide in pregnancy. What this is, is a clear read of where the evidence points: the drug is not for use in pregnancy, the animal data flags real risk, and the human safety of continued use has not been tested.

Where this lands

If you are pregnant, trying to conceive, or breastfeeding, the safest reading of the evidence is to be off semaglutide, and to plan the timing with a clinician rather than a forum thread. If you are on it and planning a pregnancy, the label points to stopping at least two months ahead^[1]. If you became pregnant while using it, that is a conversation to have quickly with a clinician who knows your history, who can weigh your own situation in a way no article can. For the wider tolerability picture, see our overview of semaglutide side effects, and for how the drug is regulated where you live, the semaglutide regulation pages.

Medical disclaimer: this article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.